Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ambrosia elatior allergen extract is a native biological allergen extract derived from the pollen of common ragweed (*Ambrosia elatior*), developed by LETI Pharma. It contains a mixture of ragweed pollen proteins, including major allergens such as Amb a 1, which possess IgE-binding capacity. The extract is primarily used for the diagnosis and treatment of IgE-mediated allergic conditions, such as allergic rhinitis, allergic conjunctivitis, and allergic asthma. In clinical development, it has been investigated in Phase 2 biological standardization studies to determine the concentration required to induce a skin prick test wheal size equivalent to 10 mg/ml histamine hydrochloride, ensuring diagnostic accuracy and safety in sensitized patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ambrosia elatior allergen extract.